Trial Size Available
Carrier-Free Available
| Document Name | |
|---|---|
| Datasheet | Download Here |
| Material Safety Data Sheet | Download Here |
| Applications | Tested Dilutions | Protocol | Note |
|---|---|---|---|
| Immunohistochemistry (IHC) | 1:100-1:200 | IHC Protocol | Manual Protocol: Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH 7.8 Target Retrieval Solution buffer. Apply the antibody at a dilution of 1:150 at 37°C for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer’s directions. |
TIMs are type I transmembrane glycoproteins with one Ig-like V-type domain and a Ser/Thr-rich mucin stalk. TIM-3 is expressed on the surface of effector T cells (CD4+ �Th1 and CD8+ �Tc1) but not on helper T cells (CD4+ �Th2 and CD8+ �Tc2). In chronic inflammation, autoimmune disorders, and some cancers, TIM-3 is upregulated on several other hematopoietic cell types. The Ig domain of TIM-3 interacts with a ligand on resting but not activated Th1 and Th2 cells. The glycosylated Ig domain of TIM-3 binds cell-associated galectin-9. This induces TIM-3 Tyr phosphorylation and pro-apoptotic signaling. TIM-3 functions as a negative regulator of Th1 cell activity. Its blockade results in increased IFN-gamma production, Th1 cell proliferation and cytotoxicity, regulatory T cell development, and increases in macrophage and neutrophil infiltration into sites of inflammation.
Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.
Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.
Information
© 2026 NeoBiotechnologies. All Rights Reserved.
Monday-Friday: 8:00am – 8:00pm Pacific Time